Company Description
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy.
It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Allen Davidoff |
Contact Details
Address: 3710 – 33rd Street NW Alberta Beach, AB T2L 2M1 Canada | |
| Phone | 403 455 7727 |
| Website | xortx.com |
Stock Details
| Ticker Symbol | XRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729214 |
| CUSIP Number | 98420Q207 |
| ISIN Number | CA98420Q3061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President and Director |
| James Neville Fairbairn C.A., C.P.A., ICD.D | Chief Financial Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Charlotte May | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 6-K | Report of foreign issuer |
| Dec 13, 2024 | 424B5 | Filing |
| Dec 12, 2024 | 6-K | Report of foreign issuer |
| Nov 25, 2024 | EFFECT | Notice of Effectiveness |
| Nov 22, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | 424B3 | Prospectus |
| Nov 15, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 24, 2024 | 6-K | Report of foreign issuer |